Dasatinib is effective against optic nerve infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia

Dasatinib, a tyrosine kinase inhibitor (TKI) of BCR–ABL and Src family kinases, inhibits BCR–ABL activity 325-fold more effectively than imatinib in vitro [1]. It is highly effective against imatin...